Scrip's Guide To Spinal Muscular Atrophy Therapies
INFOGRAPHIC: The prospects for patients with spinal muscular atrophy, the leading cause of genetic death in infants, have been revolutionized by the arrival of the first approved drug for the disease, Biogen’s blockbuster Spinraza. Now, other firms with equally revolutionary product candidates are giving chase. Scrip takes a look at the main contenders.
You may also be interested in...
Novartis and Roche have announced additional interim clinical data as their candidate spinal muscular atrophy therapies near the marketplace.
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
Executives On The Move: BioXcel Therapeutics Picks A Development Officer, A Finance Hire At RenovaCare And CANbridge Taps Takeda Talent
Immuno-oncology and neuroscience firm BioXcel Therapeutics picks a chief development officer, and stem-cell therapy company RenovaCare hires a CFO. Plus, CANbridge Life Sciences, developer of specialty health products, adds Takeda Pharma rare disease lead as global head, business development.